Abstract
Objective: The number of metastatic N2 stations is known prognostic factor in patients with non-small-cell lung cancer (NSCLC). However, involvement of N1 stations as well as that of N2 stations seems to be important in the prognosis of these patients. We therefore attempt to clarify the significance of the total number of metastatic stations in pathologic N1 and N2 NSCLCs.Methods: Patients with either pathologic N1 (n=51) or N2 (n=96) NSCL who had undergone major pulmonary resection with complete mediastinal dissection were included in this retrospective study. All positive nodes were characterized by location according to the TNM classification system. The hilar station was included with the N2 stations.Results: The total number of metastatic stations in patients with N2 disease, ranged from 1 to 8 (average 2.5), whereas that in patients with N1 disease ranged from 1 to 3 (average 1.2). The incidence of multiplestation metastasis (≥3 metastatic stations) among N2 patients (35%) was significantly higher than that among N1 patients (2%) (p<0.001). Multivariate analysis of survival showed pathologic N1 status (relative risk=0.443, p=0.013) and ≤2 metastatic stations (relative risk=0.515, p=0.020) to be significant and independent prognostic factors. Age, sex, cell type, resected lobe, and pathological T status were statistically insignificant determinates of survival.Conclusions: The total number of metastatic stations (≤2 vs≥3) is an independent prognostic indicator in patients with completely resected pathologic N1 or N2 NSCLC. The number of metastatic stations will be useful as a stratification factor in prospective clinical trials of these patients.
Similar content being viewed by others
References
Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest 1997; 111: 1718–23.
Martini N, Flehinger BJ. The role of surgery in N2 lung cancer. Surg Clin North Am 1987; 67: 1037–49.
Andre F, Grunenwald D, Pignon J-P, Dujon A, Pujol JL, Brichon RY, et al. Survival of patients with resected N2 non-small-cell lung cancer: Evidence of a subclassification and implications. J Clin Oncol 2000; 18: 2981–9.
Ichinose Y, Kato H, Koike T, Tsuchiya R, Fujisawa T, Shimizu N, et al. Overall survival and local recurrence of 406 completely stage IIIa-N2 non-small cell lung cancer patients: questionnaire survey of the Japan Clinical Oncology Group to plan for clinical trials. Lung Cancer 2001; 34: 29–36.
Liptay MJ, Masters GA, Winchester DJ, Edelman BL, Garrido BJ, Hirschtritt TR, et al. Introperative radioisotope sentinel lymph node mapping in non-small cell lung cancer. Ann Thorac Surg 2000; 70: 384–90.
Little AG, DeHoyos A, Kirgan DM, Arcomano TR, Murray KD. Intraoperative lymphatic mapping for non-small cell lung cancer: The sentinel node technique. J Thorac Cardiovasc Surg 1999; 117: 220–4.
Naruke T, Suemasu K, Ishikawa S. Lymph node mapping and curability at various levels of metastasis in resected lung cancer. J Thorac Cardiovasc Surg 1978; 76: 832–9.
Ueda, K, Kaneda Y, Saeki K, Fujita N, Zempo N, Esato K. Hilar lymph, nodes in N2 disease: Survival analysis of patients with non-small-cell lung cancer and regional lymph node metastases. Surg Today 2002; 32: 300–4.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ueda, K., Kaneda, Y., Sakano, H. et al. Independent predictive value of the overall number of metastatic N1 and N2 stations in lung cancer. Jpn J Thorac Caridovasc Surg 51, 297–301 (2003). https://doi.org/10.1007/BF02719381
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02719381